Publications by authors named "Lawrence Garbo"

Claim this Profile
A
A Phase Ib multicenter, dose-escalation study of the polyamine analogue PG-11047 in combination with gemcitabine, docetaxel, bevacizumab, erlotinib, cisplatin, 5-fluorouracil, or sunitinib in patients with advanced solid tumors or lymphoma.
Tracy Murray Stewart, Daniel Von Hoff, Michael Fitzgerald, Laurence J Marton, Carlos H Roberto Becerra, Lawrence E Garbo

Cancer Chemother Pharmacol· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of CD30-Expressing Germ Cell Tumors and Sex Cord Stromal Tumors with Brentuximab Vedotin: Identification and Report of Seven Cases.
Costantine Albany, Lawrence Einhorn, Lawrence Garbo, Thomas Boyd, Neil Josephson

Oncologist· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer.
Alex A Adjei, Donald A Richards, Anthony El-Khoueiry, Fadi Braiteh, Carlos H R Becerra, Lawrence Garbo

Clin Cancer Res· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An innovative, multi-arm, complete phase 1b study of the novel anti-cancer agent tasisulam in patients with advanced solid tumors.
Robert M Jotte, Daniel D Von Hoff, Fadi Braiteh, Carlos R Becerra, Donald A Richards, Lawrence Garbo

Invest New Drugs· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of 24-month outcomes in chelated and non-chelated lower-risk patients with myelodysplastic syndromes in a prospective registry.
Roger M Lyons, Billie J Marek, Carole Paley, Jason Esposito, Lawrence Garbo

Leuk Res· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: a phase 3, open-label, randomised trial.
Edward S Kim, Marcus Neubauer, Allen Cohn, Lee Schwartzberg, Lawrence Garbo

Lancet Oncol· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Azacitidine favorably modulates PSA kinetics correlating with plasma DNA LINE-1 hypomethylation in men with chemonaïve castration-resistant prostate cancer.
Guru Sonpavde, Ana M Aparicio, Feng Zhan, Brittany North, Robert Delaune, Lawrence E Garbo

Urol Oncol· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer.
David S Ettinger, Robert Jotte, Paul Lorigan, Vicram Gupta, Lawrence Garbo

J Clin Oncol· May 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Results of a Phase II trial of gemcitabine, mitoxantrone, and rituximab in relapsed or refractory mantle cell lymphoma.
Lawrence E Garbo, Patrick J Flynn, Margaret A MacRae, Mary A Rauch, Yunfei Wang

Invest New Drugs· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Thalidomide and rituximab in Waldenstrom macroglobulinemia.
Steven P Treon, Jacob D Soumerai, Andrew R Branagan, Zachary R Hunter, Christopher J Patterson, Lawrence Garbo

Blood· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis